Version 1
: Received: 22 August 2024 / Approved: 23 August 2024 / Online: 23 August 2024 (12:24:46 CEST)
How to cite:
Tsolakidis, D.; Zouzoulas, D.; Sofianou, I.; Karalis, T.; Chatzistamatiou, K.; Theodoulidis, V.; Topalidou, M.; Timotheadou, E.; Grimbizis, G. External Validation of the New 2023 FIGO Staging System in Endometrial Cancer Patients: 12-Year Experience from an ESGO Accredited Center. Preprints2024, 2024081708. https://doi.org/10.20944/preprints202408.1708.v1
Tsolakidis, D.; Zouzoulas, D.; Sofianou, I.; Karalis, T.; Chatzistamatiou, K.; Theodoulidis, V.; Topalidou, M.; Timotheadou, E.; Grimbizis, G. External Validation of the New 2023 FIGO Staging System in Endometrial Cancer Patients: 12-Year Experience from an ESGO Accredited Center. Preprints 2024, 2024081708. https://doi.org/10.20944/preprints202408.1708.v1
Tsolakidis, D.; Zouzoulas, D.; Sofianou, I.; Karalis, T.; Chatzistamatiou, K.; Theodoulidis, V.; Topalidou, M.; Timotheadou, E.; Grimbizis, G. External Validation of the New 2023 FIGO Staging System in Endometrial Cancer Patients: 12-Year Experience from an ESGO Accredited Center. Preprints2024, 2024081708. https://doi.org/10.20944/preprints202408.1708.v1
APA Style
Tsolakidis, D., Zouzoulas, D., Sofianou, I., Karalis, T., Chatzistamatiou, K., Theodoulidis, V., Topalidou, M., Timotheadou, E., & Grimbizis, G. (2024). External Validation of the New 2023 FIGO Staging System in Endometrial Cancer Patients: 12-Year Experience from an ESGO Accredited Center. Preprints. https://doi.org/10.20944/preprints202408.1708.v1
Chicago/Turabian Style
Tsolakidis, D., Eleni Timotheadou and Grigoris Grimbizis. 2024 "External Validation of the New 2023 FIGO Staging System in Endometrial Cancer Patients: 12-Year Experience from an ESGO Accredited Center" Preprints. https://doi.org/10.20944/preprints202408.1708.v1
Abstract
Background and Objectives: The new molecular classification of endometrial cancer continuously changes the management of the disease in every day clinical practice. Lately, FIGO released a new staging system for endometrial cancer, which incorporates molecular sub-stages and subdivides further early-stage disease. The aim of this study is to investigate the differences between the two FIGO staging systems and evaluate the prognostic precision of the new one. Materials and Methods: We retrospectively analyzed the records of patients with endometrial cancer that were fully treated in the 1st Department of Obstetrics-Gynecology, 2012-2023. Patient characteristics, oncological outcome and follow-up information were collected. The primary outcomes were the stage shifts and the survival data. Results: 67 (15.5%) patients had a stage shift and the majority of them concerned early-stage disease and specifically up-shift from 2009 stages IA and IB to 2023 stage IIC. Concerning, survival a better median and 5-year PFS was present in Stage II disease and when compering the prognostic precision of the two FIGO staging systems no significant difference was present. Conclusions: The new 2023 FIGO staging system better distinguishes early-stage endometrial cancer into its prognostic groups and seems to be as precise as the old 2009 FIGO staging system.
Keywords
endometrial cancer; cancer staging; prognosis; survival
Subject
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
